DAM
IMDZ

Doheny Asset Management’s Immune Design Corp. IMDZ Stock Holding History

Doheny Asset Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-611,550
Closed -$6.33M – 118
2017
Q3 		$6.33M Buy
+611,550
New +$6.02M 2.91% 8

Other funds holding IMDZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Doheny Asset Management's IMDZ Position: Q4 2017 in Review

Doheny Asset Management sold out of Immune Design Corp. (IMDZ) in Q4 2017, closing a stake of 611,550 shares — an estimated $6.33M sold.

Doheny Asset Management first reported a position in IMDZ in Q3 2017 and held it in 1 quarter. The position peaked at $6.33M in Q3 2017. 76 funds tracked by Wall St. Rank hold IMDZ as of Q4 2017.

  • Doheny Asset Management reported no remaining Immune Design Corp. position as of Q4 2017 after selling out during the quarter.
  • Doheny Asset Management sold 611,550 Immune Design Corp. shares in Q4 2017, an estimated $6.33M.
  • Doheny Asset Management first reported a position in Immune Design Corp. in Q3 2017 and held it in 1 quarter.
  • Doheny Asset Management's Immune Design Corp. position peaked at $6.33M in Q3 2017.
  • 76 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2017.

Based on Doheny Asset Management's 13F filing for Q4 2017, filed 15 Feb 2018.